DocGo Inc. (DCGO) Earnings Call Transcript & Summary

November 6, 2023

NASDAQ US Health Care Health Care Providers and Services earnings 60 min

Earnings Call Speaker Segments

Mike Cole

executive
#1

Thank you, operator. Prior to handing things over to management, I'd like to offer a few comments about forward-looking statements. Everything shared on this conference call that isn't a statement of historical fact counts as a forward-looking statement. Terms such as may, will, plan, potential, could, <<inaudible>>, outlook, design, anticipate, aim, believe, estimate, expect, intend, guidance, confidence, target, project, along with similar expressions, might be employed to flag such forward-looking statements. Such forward-looking statements don't constitute guarantees regarding future performance, and we are unable to assure you that our plans, intentions, outcomes, results or expectations will be achieved or realized. Forward-looking statements carry inherent exposure to significant risks, uncertainties and assumptions, a great many of which lie outside our control and could lead our actual results or outcomes, or when those results or outcomes occur, to diverge materially from what our forward-looking statements contain. Among these risks, uncertainties and assumptions are, without limitation, those covered in our Risk Factors and other sections of DocGo's annual report on Form 10-K, quarterly reports on Form 10-Q and additional reports and statements DocGo has filed with the SEC, to which we direct your attention. Actual outcomes and results, or their timing, could diverge materially from what these forward-looking statements express or imply. Furthermore, today's call references certain non-GAAP financial measures. Reconciliations of those non-GAAP financial measures against the most directly comparable GAAP financial measures appear directly within this call or are included in our earnings release, which is posted on our website, docgo.com, and also filed with the Securities and Exchange Commission. The information in this call is accurate only as of the date under discussion. Investors shouldn't assume that statements will stay relevant and operative at a later point. We assume no obligation to update any information discussed on this call to reflect events or circumstances occurring after the date of this call, or to reflect new information or the occurrence of unanticipated events, except to the extent the law requires. At this time, it's now my pleasure to turn the call over to Mr. Lee Bienstock, CEO of DocGo. Lee, please go ahead.

Lee Bienstock

executive
#2

Thanks, Mike, and thanks to everyone for being here today. The third quarter represented the biggest growth we've seen since the company began, and I feel tremendous pride in how sharply our team has stayed focused as we broadened our service offerings, executed operationally and delivered financially. Throughout the quarter, and after it closed as well, we kept growing with existing clients while bringing on new ones and securing wins on RFPs. Above all, our team keeps pushing to widen access to care for the people who need it most. During the third quarter, cumulative patient interactions since our inception surpassed 7.5 million. Our team has grown to over 6,000 employees — that's more than double the headcount from when I joined. Everywhere we operate, appetite for our services remains robust. As a result, we are increasing our full-year 2023 revenue projection from the prior range of $540 million to $550 million up to $615 million to $625 million. Additionally, we are raising our full-year 2023 adjusted EBITDA forecast to $50 million to $55 million, up from the earlier $48 million to $53 million. While a significant portion of Q3 press attention centered on our migrant-related efforts, that represents just a fraction of what DocGo accomplished during the quarter. Just to give you the full scope of what happened in Q3 on its own: over 158,000 patients received services from DocGo. More than 50,000 patients were contacted by our patient engagement team. RPM, VCM, and CIED monitoring were provided to over 46,000 patients. And because demand for what we offer kept climbing, our staffing headcount increased by over 26% during that quarter. We also expanded our clinical capabilities further so we could tackle more than 30 different care gaps within patients' homes — areas such as bone density measurements, colon cancer screenings, diabetic retinal screenings, and annual wellness visits. At the time and location where patients need care, DocGo provides it. It's really gratifying to watch so many clients recognize the value our offerings deliver and keep expanding the scope of work they give us. I feel great about all the efforts we're making to support patients together with our insurance collaborators, government and municipal population health initiatives, and hospital system clients. In each of these three core areas, I'd like to review what we've accomplished, how far we've come, and what lies ahead. Let's begin with our insurance collaborators and provider groups that take on risk: the opportunity in the marketplace tied to large insurers and value-based care allies — including the agreements we've finalized with health care partners, EmblemHealth and others — is one domain where our results have been substantial. We stepped into this space with pilot programs late last year, and most of those partnerships we've launched have grown over the past 6 months, fueling broader commercial rollouts. During the prior quarter, we told everyone we anticipated having 73,000 patients assigned so we could close care gaps and deliver primary care through these arrangements with 4 payers; thus far, 59,000 of those patients have been assigned to us, and we've broadened our clinical services to cover a broad array of primary care offerings, such as annual wellness visits for Medicare members and pediatric checkups, which include childhood vaccinations and nutritional counseling for Medicaid members. We expect the number of patients assigned to us to grow strongly, and we view that as a big opportunity for DocGo, with many years of growth still ahead. In our population health programs, the work we do for migrants continued to grow significantly during the quarter, and we've launched 4 new sites in only the past 6 weeks; we expect to keep working closely with our city partners to provide asylum seekers with medical care, behavioral health care, basic necessities and support services, helping them move out of the program and into a position of self-sustainability as quickly as possible. Unlike the negative media coverage early on, we recently reported that the contract has been registered and payments have begun. Also, a new independent report from the New York State Office of Temporary and Disability Assistance found that our programs were operating as intended and that needs are being addressed. In our view, this report gives an accurate picture of DocGo's work and the quality of our programs, along with how committed, diligent, and dedicated we are to making better the health, safety, and overall well-being of everyone receiving our care. Bidding on municipal and corporate RFPs stayed a central priority and a significant opportunity for the company. We found out recently that a sizable federal border control RFP did not go to us, though we have plenty of other opportunities that we are enthusiastic about. As we move forward, we intend to talk about this channel as a collection of possibilities, rather than giving so much fine-grained information about any particular RFP. Our plan is to go after Mobile Health—covering both medical and behavioral health—along with medical transportation and municipal opportunities, pursuing them inside the areas where we already operate while also looking to move into additional states, all of which fits with the capabilities we continue to build. With our partners in hospital systems and medical transportation, we're likewise seeing a meaningful number of new contract wins. Here are a few to mention. We recently made public our agreement with Main Line Health systems in the Northeast, which we anticipate will amount to roughly $23.5 million in potential revenue across 3 years, and we intend to expand this relationship further in early 2024. On top of that, we secured a significant contract for medical transportation in the U.K., worth $34 million across the coming 5 years, and the major New York Health and Hospitals agreement we told you about early this year has now been completely implemented, exactly as scheduled. The way this segment is delivering makes us quite happy, and we anticipate ongoing robust organic growth over the next several quarters. With that, I'll pass things to Norm for the financial discussion. Norm, the floor is yours.

Norman Rosenberg

executive
#3

Thanks, Lee, and good afternoon to everyone. For the first — sorry, for Q3 of 2023, total revenue came in at a company record of $186.6 million. That figure was 49% above our previous record, set just a quarter earlier in Q2, and it worked out to a 79% rise compared with the third quarter of 2022. Mobile Health revenue in Q3 of 2023 reached $139.3 million, which is up 74% versus the second quarter and 82% above the third quarter of last year. Although the bulk of those revenue gains came from expanding our migrant services contracts, we did see growth across a number of projects. A few of our migrant services programs involve delivering what we refer to as Total Care Services, which cover shelter and related items alongside core medical services; going forward, these nonmedical services should make up a smaller share of DocGo's overall revenue base in future quarters, since our newly awarded or launch contracts lean more toward medical related services. Transportation Services revenue climbed to $47.2 million in Q3 of 2023, up 4% from this year's second quarter and more than 70% above transportation revenues in the third quarter of 2022. Almost every core transportation market saw year-over-year revenue growth, which continues the momentum that started in the second half of last year. During the third quarter, Mobile Health revenues represented roughly 75% of total revenues, while Transportation was roughly 25%. That split is nearer to our expected mix of revenues than what we saw in the prior 3 quarters. From early indications in Q4, it looks like Mobile Health will probably keep accounting for over 75% of total revenues in the fourth quarter of this year. At the close of the third quarter, our revenue backlog — defined as remaining revenue from projects that have been awarded but not yet fully rolled out — stood at $430 million, up from $325 million at the end of Q2. We posted net income of approximately $4.6 million in Q3 of 2023, versus net income of $1.3 million in the second quarter and net income of $2.5 million in the third quarter of 2022. Adjusted EBITDA for the third quarter of 2023 came to $16.7 million, up 84% from adjusted EBITDA of $9.1 million in the second quarter and nearly double the $8.4 million in last year's third quarter. The adjusted EBITDA margin in Q3 was 9%, compared with 7.3% in the second quarter and 8.1% in the third quarter of 2022. Total gross margin percentage during the third quarter of 2023 was 29.5%, down from 33.4% in the second quarter and 31.7% in the third quarter of 2022. Gross margins in the third quarter took a hit from the increase in revenues and the associated project ramp-up costs that came with the recent launch and ramp-up of new projects. As we discussed earlier, our revenue grew by approximately $60 million just since the end of the second quarter. We seized the chances that came our way to speed up growth, accepting the expected downside of gross margins being temporarily low. Earlier, we had expected gross margins to keep getting better each quarter through 2023, but we had also noted that overall margins might be affected by when new projects launched and ramped up, and how big they were. That is precisely what happened in Q3 of 2023. Still, it should be pointed out that gross margins remained over 100 basis points above the recent trough in the first quarter of this year. To be specific, when revenue growth speeds up, we usually experience labor costs that are higher than usual because of overtime rates exceeding what we planned and more reliance on subcontracted labor, which is comparatively pricier. In Q3, overtime across the company stood at 17%, far above our goal of 5% to 10%. Subcontracted workers made up nearly 50% of all field labor costs. Normally, we want that figure to be nearer to the 25% range. In the third quarter, the Mobile Health segment's gross margins came in at 28.8%, versus 34.9% in the second quarter and 34.8% in the third quarter of 2022. For the Transportation segment, gross margins grew for a fifth straight quarter, reaching 31.7% in Q3 of 2023, compared with 30.7% in the second quarter and 23.2% in Q3 of 2022. Now looking at operating costs. Operating expenses represented 24.8% of total revenues in the third quarter of 2023, a big drop from 32.1% in the second quarter, and versus 27.7% in the third quarter of 2022. If we exclude depreciation and stock comp expenses from that same comparison, operating expenses were 20.7% of total revenues in the third quarter of 2023, down from 26.4% in the second quarter and 23.7% in the third quarter of 2022. As revenues have grown, operating expenses have fallen as a share of total revenues, which has driven operating margin expansion. So, even with lower gross margins, adjusted EBITDA margins in Q3 exceeded those in either Q2 or Q3 of last year, as I said before. Now shifting to the balance sheet. On September 30, 2023, total cash and cash equivalents, including restricted cash, came to $67.3 million, compared with $123.8 million at the close of Q2. The drop in cash balance mostly stems from a rise in accounts receivable, which mirrors the revenue increase in Q3, coming after sequential revenue growth in Q2; that revenue gain was mainly fueled by our government business, such as our migrant related work, which has a long initial payment cycle. But since the third quarter ended, we have started getting payments for this completed work. And as we bring those accounts receivable down, we anticipate near-term collections will be sufficient to push our total cash balance up in later periods, even with our continuing working capital needs. To strengthen our working capital position, we tapped our revolving credit facility for $25 million after the quarter closed. That leaves $65 million of borrowing capacity still available to us. We regard this credit as short term in nature. Once our biggest unpaid invoices come in, our intention is to reduce what we owe. That said, we do anticipate these recent working capital pressures will stick around, since we remain in growth mode with a growing payroll and we're settling substantial bills with our vendors, all considerably ahead of collecting payments from those customers. Now to what we expect for the rest of 2023. We foresee demand from our customers staying strong for both Mobile Health and Transportation Services. Our results in Q4 so far have us quite optimistic. Early signals indicate that we've sustained the revenue momentum from Q3, during which we saw revenues rise each month and margins expand across every month of the third quarter. Though Q3 revenues came in far above what we had originally expected, we treat that outperformance as an acceleration, not as an aberration. In Q3, we reached a spot on our growth curve that we had initially believed was at minimum another quarter or 2 away. Still, we don't think this revenue is onetime. So, as Lee said earlier, we are lifting our revenue guidance for the full year 2023, and we now anticipate revenues falling between $615 million and $625 million, versus our most recent raise in revenue guidance to the $540 million to $550 million range. Let me remind everyone that the original revenue guidance for 2023 was $500 million to $510 million. This higher revenue guidance range would amount to year-over-year top line growth of roughly 40% on an as-reported basis. But when we shift $75 million of mass COVID testing out of our 2022 revenue baseline, and given that we've received no material mass COVID testing revenues so far in 2023, we would then anticipate top line growth of almost 70% when comparing full year 2023 against full year 2022; we're also raising our guidance for adjusted EBITDA to the range of $50 million to $55 million, up from our recent guidance of $48 million to $53 million, which had already been increased last quarter from our initial 2023 guidance range of $45 million to $50 million; as for 2024, it's too early for me to offer any specific details right now. Even so, we expect a strong finish to 2023, which our guidance implies, and we believe our backlog numbers give us solid visibility into continued growth in 2024. With that, I'd like to hand the call back over to Lee.

Lee Bienstock

executive
#4

Thanks, Norm. In my role as CEO, I want to guide the company into a new era shaped by strong execution, greater maturity, and a clear sense of direction — with DocGo concentrating on what I view as our three largest opportunities for expansion. My vision for where this business is going is sharp: we help our three customer verticals — health systems, municipalities, and insurers — keep patients from being admitted to the hospital. To begin, as I mentioned earlier, closing care gaps along with additional potential involving large insurance carriers and value-based care provider organizations; the initial signals look promising, and we are chasing numerous opportunities that ought to increase the number of patients assigned to us, extend our geographic reach, and broaden the range of services we offer. Also involved in this push are the solutions we offer for remote patient monitoring and chronic care management. Our view is that by combining in-home and virtual medical visits with remote monitoring and care management, we are able to effectively treat certain patients whose cases are among the most complex — specifically those responsible for the greatest costs. Through creative programs in which we might share in the savings that get generated, we intend to bring this capability to our health plan partners. The second area is programs aimed at avoiding readmissions, done in partnership with major hospital systems. For our customers, these programs have historically yielded strong results, and we intend to aggressively chase growth opportunities within this vertical. Last of all, we will keep focusing on our RFP channel along with what we regard as sizable market opportunities. During the past twelve months, we've significantly improved how well we can spot and pursue these kinds of projects, and we anticipate continuing to secure progressively bigger deals as time goes on. The common thread across those 3 markets is that we possess the customer data necessary to support the value proposition DocGo provides; at this point we just need to execute and expand it, and that is precisely where we intend to concentrate our efforts. We see numerous greenfield possibilities awaiting us across the 3 verticals referenced earlier in this call, and my objective as CEO is to establish the groundwork for substantial growth at DocGo well into the future. We're now ready to take questions, so I'll turn things over to the operator. Operator, the floor is yours.

Sarah James

analyst
#5

I'd like to discuss what Norman said regarding the operating expense ratio. The remarks about scale are helpful, but does that mean this is now the baseline? Or are there other factors, such as the timing of investment spending, that gave the quarter a boost?

Norman Rosenberg

executive
#6

Of course, Sarah. Mostly, what happened this quarter does represent the new baseline — since we'd anticipate revenue holding steady around this amount or increasing beyond it, that sets a fresh revenue floor. Nothing stands out that would push SG&A up materially, apart from the usual quarter-over-quarter bumps that come as we keep expanding our infrastructure, and keep in mind, we're still playing catch-up. Right now we're a company with $186 million in quarterly revenue, so that means roughly $725 million to $750 million on an annualized basis. Our situation has always required letting infrastructure catch up. Beyond that, there's nothing particular to point to. No major marketing initiative is coming down the pike or anything of that sort beyond the routine; therefore, we'd expect to likely maintain ratios along these lines. One caveat: this won't simply keep climbing forever. We won't reach a stage where SG&A equals 10% of revenue. At some point, SG&A probably jumps in a step function. Apart from that, you ought to see comparable leverage in the quarters ahead to what Q3 delivered.

Sarah James

analyst
#7

And then one more thing. You all said that payments on New York HPD are happening. Now that October is behind us, could you help us understand where cash or receivables stand on that? Is it still behind where a typical contract would be? Have you all caught up?

Lee Bienstock

executive
#8

Yes, I — this is Lee — go ahead, Norm.

Norman Rosenberg

executive
#9

Alright, yes — apologies, we're probably still playing a bit of catch-up here. When it comes to a lag, there are a few angles worth examining. One is to compare the invoice dates against the service dates and then against where things stand now; from that angle, I'd say what we're seeing runs somewhat longer than the norm for us. The bigger element, though, is the point at which the contract becomes registered for each of these municipal agreements, and that's exactly why we put so much emphasis on getting the contract registered. It's also why we referenced it in an 8-K. Until registration happens, no contract gets paid — not even one that's completely signed, and services don't get paid for either, until that registration is in place. Fortunately, registration for this contract has gone through. If I consider our position in the payment cycle relative to when the contract was registered, we sit entirely inside the usual band we've observed with various municipal agencies and numerous different municipalities. We've now spent 3.5 years operating in the municipal space. So nothing here falls outside the normal pattern. The only thing is that the number itself is really large.

Lee Bienstock

executive
#10

Absolutely. And Sarah, the sole point I'd tack on there, like Norm mentioned, is that in my view this is — what we've seen is that situation where we exchange the invoice back and forth and eventually get it into the proper rhythm the way the municipalities prefer to receive it, and after that payments come along on a pretty consistent basis. So it's quite representative of how things have gone for us, and earlier contracts were the same in this regard, though as Norm pointed out, this instance involves a bigger figure.

Richard Close

analyst
#11

Okay, perhaps a quick follow-up regarding Norm on that point. Could you take us through what you're thinking about accounts receivable and how that figure ought to be viewed for the fourth quarter? I realize you aren't providing 2024 guidance, but what about the direction of that figure?

Norman Rosenberg

executive
#12

Absolutely, Richard. Allow me to address that and share how we approach overseeing our AR portfolio from the top down. If you consider the figure itself, it's an extremely, extremely big figure, correct? Our AR exceeds $200 million. There are — clearly 3 distinct angles from which to consider it; you can consider it through days sales outstanding, and currently AR stands above $200 million. Yet at this point we're generating nearly $200 million, $186 million, almost $190 million in quarterly revenue. So purely from the straightforward computation of days sales outstanding, although it's elevated relative to, say, the prior quarter end at $ 630 million, it's in fact below where it stood in March of 2023; so that's something worth factoring in. It remains a figure that is big, that is extremely large. What we examine is whether, throughout the various buckets — the various aging buckets within our accounts receivable — we've observed any weakening in our portfolio. Fortunately, we haven't; we in fact — beneath the headlines, we in fact performed quite well at collecting some of our comparatively aged receivables this quarter, on both the Transportation side and Mobile Health. The next item we prefer to examine is the composition of the portfolio within those various buckets. So when I consider what's current, correct, which is generally characterized as 0 to 30 days. At March, simply to provide a bit of a baseline or comparison, at the close of the first quarter, merely roughly 25%, 26% of our AR portfolio sat under 30 days. By June 30, that figure had reached roughly 56%. And at present, given — clearly, it's simply how the arithmetic works, given that so much of this revenue stems from activity during this quarter. As of September 30, close to 2/3. So roughly 63%, 64% of our AR is current. Likewise, examining the opposite side of the equation, when I check the over 90, it's a smaller figure than what we've witnessed. When I check over 180, perhaps 10%. And I'd note that in this business, particularly on the ambulance side, we continue collecting a considerable amount of what's older than 180 days. Frequently we'll collect items even reaching 360 and beyond. To sum up my response, the accounts receivable balance is extremely sizable. It should begin declining since we anticipate moving to an improved payment schedule, for instance, with certain bigger clients such as HPD or another municipal entity. Yet simultaneously, our revenues are expanding considerably. Consequently, that will keep exerting pressure on the total figure; however, what we monitor most intently is the way the aging categories are distributed, and that is being handled fairly effectively.

Richard Close

analyst
#13

For a follow-up, could we take another look at gross profit margin and perhaps dig a bit deeper into what you said about it and how you see that figure developing down the road?

Norman Rosenberg

executive
#14

Yes, of course. As I said during my prepared remarks, across the past 2 quarters we discussed fairly often our expectation that margins would rise on a sequential basis quarter by quarter; we recorded 28.1% gross margin. In Q1, I believe it reached 33.4%, roughly that figure in the most recent quarter, and now we're stepping backward. Yet what we consistently said was that this depended on growth occurring at a fairly stable pace; and what showed up in the quarter just ended was considerably more revenue than I think we had projected a few months back when we discussed expanding that revenue, clearly — expanding that gross margin quarter over quarter; and in looking at it, no single project is — we don't — we have not swapped high-margin revenue for low margin revenue. Nothing like that is taking place. It truly sits in the labor areas, where a subcontracted labor percentage is elevated relative to what would normally be the case, and over time is elevated relative to what would normally be the case. The encouraging part is that — those metrics, those KPIs, which cause the margins to get better quarter by quarter. So it stood at one level in July, got better in August, and improvement started in September. So that's — those are the factors behind it — And whenever you're going to introduce the new product — new project launches and as a result, a lot of revenue in a — single quarter, that's the pressure you'll face. That said, without committing to what I believe Q4 gross margins will be, I will say that in terms of direction, margins come in above what you're seeing this quarter. What you're seeing this quarter on one side, regarding revenue, that turns into our new revenue baseline from which we believe we can grow. There's no genuinely nonrecurring revenue in the quarter. This is actual recurring revenue; on the other side, regarding the gross margin figure, I would describe it as having been temporarily beneath what it truly should be. It isn't our run rate of gross margin. It isn't the run rate of gross margin we witnessed exiting the quarter. So if I would normally take — I mean, if I simply took the September month margin and used it for Q4, that alone would produce a higher gross margin. So that somewhat feeds into what we expect for the fourth quarter.

David Larsen

analyst
#15

Nice work on the third quarter. Lee, could you perhaps share some thoughts regarding the connection you have with New York City and New York State, plus that agreement specifically? Could you give us a quick refresher on precisely what you're providing for the migrants? What portion of these migrants are families that include kids whom you're assisting? Then, from what I gather, based on how the contract is structured at present, it runs roughly 1 year, lasting through mid-2024. In your estimation, what's the likelihood it might get extended? And finally — apologies for such a lengthy question — have you managed to sit down with New York's comptroller? And regarding that matter about the specifics of the invoices, have you been in a position to resolve that issue? I'm at an airport, so sorry about the noise behind me.

Lee Bienstock

executive
#16

That's fine. Appreciate it, David. I'll begin with the opening portion of what you asked, our connection with the city; as was referenced, we've partnered with the city for more than 3 years; we've worked on a variety of population health initiatives. As I noted, we also deliver the medical transportation for each of the 11 public New York City Health and Hospitals sites. So we've partnered with the city across quite a few years. You've heard us discuss the SHOW program, meaning the Street Health Outreach and Wellness program. You've heard us discuss what we do with the Department of Home Services. You've heard us discuss now what we do with Housing Preservation and Development. You've heard us discuss what we do with New York City Health and Hospitals; so we've assisted New York City across a broad spectrum of population health and medical transportation requirements ever since our partnership with the city began more than 3 years back, and together we've delivered care to millions of New Yorkers. That makes us extremely proud. As for the asylum seeker and migrant care efforts, it truly began when the first buses showed up at Port Authority, and we in fact supplied the initial paramedic units at Port Authority when those first buses began arriving from our southern border; that's genuinely how our joint efforts began; we supplied the paramedic teams, and we're conducting health screenings, infectious disease screenings and so on for the asylum seekers upon their arrival. From there it has basically expanded into all the services we've been referencing. And truly, it has expanded into what we refer to as our Total Care services and spans medical care that might involve infectious disease screenings, urgent care and other medical care plus vaccinations too. It covers behavioral health, which encompasses depression screening and additional case management efforts and intensive social work too, and then obviously includes the program's other assets so we can deliver the total care that asylum seekers require when they arrive. Every bit of what we're aiming for is to assist them in reaching safety, and then, in the end, to adjust and, as we put it, move on from the program; that's the support we've been delivering. Each location offers a somewhat different mix of services, yet that full array is what we've been giving. You inquired about the share who are families coming in with kids; in fact, among the asylum seekers under our care, a substantial majority are family units that include children. At most of the sites, it's families with kids. That means we deliver everything from care for 2-year-olds and pediatric services right up to people as old as 80, which is what we've been doing. So the bulk of our families are children. Right, and additionally, David, regarding how long the contract runs, as you hinted, the agreement — the HPD agreement covering the asylum seeker effort we're engaged in — lasts 1 year, and that's really standard for the contracts we hold with the city. A number of them have gotten extensions. A number have been awarded again. We absolutely expect that some parts will go out for RFP and similar processes, which is extremely typical of the way we've partnered with the city for more than 3 years now, as I noted. That HPD agreement was signed and kicked off in May. So if you track that 1-year timeline, it would run through May of next year; yet once more, truly, what we want is to supply whatever services the city requires, the medical treatment and behavioral health treatment the city requires, for as long as the city requires it. And we aim to support the city in helping asylum seekers so they can basically carry on with their lives, transition out of the program, and get whatever services they need for however long the city asks us to deliver them, for however long the asylum seekers require it.

Michael Latimore

analyst
#17

Congratulations on the incredible top-line and EBITDA improvement. I want to return to the cash situation briefly. Could you perhaps give a slightly tighter range on that? In other words, do you expect cash generated from operations in Q4 to come in higher or lower than EBITDA? And after that, roughly by the close of the year — which month do you figure it will have been paid through by then, say?

Norman Rosenberg

executive
#18

Right. This is Norman, and I'll handle that question. It gives me a chance to note that, in contrast to earlier quarters, our 10-Q for the period has already been submitted; we essentially did that alongside the earnings announcement on a regular basis. Much of the data is therefore in the release regardless, though the fuller, more granular information is out there now. Now, regarding cash from operations versus EBITDA, one item you'll observe is that everything affecting operating cash flow came purely from working capital. Apart from that, on what we refer to as the P&L side of operating cash flow, that figure was already quite near matching the EBITDA figure. The real question, I suppose, is when we'll reach the stage where working capital stops being a weight on operating cash flow. That could occur in Q4. Honestly, it will hinge largely on when particular payments arrive for us relative to the pace at which we expand and the pace at which our cost base expands, since we're disbursing funds for labor and for numerous other items owed to vendors ahead of being paid by the city; that leaves us with a continuing negative cash cycle on those programs, whether the payer is the city or some of our bigger municipal or other clients. So my expectation is that here we are in early November. We have roughly — is it 6, 7 weeks remaining in the year; we expect to be fairly well current by the time the year ends, or at least that's what we're hoping. It's simply a bit unpredictable, since we aren't the party that pays us. And we're talking with the various finance departments — the relevant finance departments at different levels — on a daily, or more nearly daily, basis, whether that's me, whether that's Lee, whether that's individuals on our finance or operations teams. So a great deal of conversation is taking place. I ought to mention, and this connects to something David raised in the questions about 4 years, that any deceleration in payment is not — no deceleration in payment is tied in any manner, shape or form to disputes. When it comes to the amounts we're billing and the categories we're billing them under, there's been no disagreement. It's just that every so often they ask for additional documentation, which we possess and simply need to forward along their preferred channel. My sense is that once we establish a solid cadence together and a steady payment rhythm, the catch-up will happen fairly fast. Regarding the schedule — I won't get into the strategic specifics, but a schedule has been provided to the city showing when we anticipate being paid. Should they adhere to it, going month by month, invoice by invoice, we'd be mostly current by year-end, which reflects the usual 60 to 90-day lag between service delivery and payment, standard across all our contracts. Clearly, that would make a significant difference to what we report in Q4. I'm somewhat hesitant to project where the balance sheet will stand at year-end, since many factors could shift things. What I'd be watching for is an improvement — a decline in sales outstanding and other indicators on the operating cash flow side showing that we're beginning to catch up.

Michael Latimore

analyst
#19

Also, during Q2, I realize you got a chosen set of staffing agencies into agreements designed perhaps to provide them additional volume, yet on advantageous conditions as well. Could you explain — I realize — plus I realize this quarter, you've scaled up extremely fast on this fresh arrangement, but could you share details about those agreements, the staffing agency connections, and the conditions? Are they each being satisfied roughly as anticipated, I suppose, considering this sort of swift early ?.

Lee Bienstock

executive
#20

Yeah. So Mike, certainly. So we're truly putting every one of those agreements to use fully during Q2, Q3 and afterward, every one of those partners — we refer to them as partners since they're assisting us to grow enormously. Every one of those partners, every one of those agreements is delivering as anticipated. Every bit of the bargaining and drafting of those agreements is in fact executed nicely. And so yeah, we're certainly gaining a great deal from those throughout Q2 and Q3 and continuing across the remaining portion of the year here.

David Grossman

analyst
#21

Lee, I want to follow up on something. In your prepared remarks, you touched on the commercial side of the business, and from what I can tell, you're still sitting at 73,000 lives across 4 payers, with about 60,000 of those lives assigned as of right now, I believe. Could you shed any more light on how we should expect these pilots to build on the revenue side across the coming 12 months? And is there any new business in the pipeline that could help us understand how this segment ought to scale over roughly the next year?

Lee Bienstock

executive
#22

Yes. Of course, David. Glad to walk through it. When we think about that business, we consider a whole range of metrics. The first one, which you brought up, is how many patients get assigned to us. That figure — I want to see it climb. It is climbing. It's climbing quite substantially. So we want that growth to keep going. Beyond that, I monitor — and my team monitors — conversions, meaning how many of those patients do we actually reach, do we visit to close the care gap, do we get into the home; and I expect that figure will rise as well over time as our teams become increasingly specialized, increasingly well trained, and as we accumulate more experience. And as we add more and more talent to the team, that figure has been rising too. In fact, just last week, I was reviewing a metric showing the highest conversion rate since we began. So that metric is one I want to see increase, and it is increasing, and I'm happy with where we stand on how many assigned patients end up engaging with us. And clearly, our model is distinctive in that we don't phone the patients who walk into our office — instead, we travel to where they live. And clearly, we can lower the barriers to access and deliver care to the patients who need it. Nearly every one of these patients hasn't laid eyes on their primary care provider in more than 1 year. And a lot of them are chronically ill — in fact, almost all are chronically ill; so they need care gaps closed, they need intervention, they need the services we provide. So I track assigned patients, and I track conversions. Another thing I track, and I'm quite happy about it — I brought it up on the call — is how many care gaps we address, and how broad our service offerings are. We believe this gives us a significant additional edge over competitors. Clearly, mobile delivery is one competitive advantage, and our wide array of care gaps is another. We hear a great deal from the market that what we provide — the breadth of our services — is genuinely quite unique as well. What I want to see is our care gap offerings expanding further and further, along with additional clinical services, delivered to a growing population of chronically ill patients who require them. And when that happens, our health plan partners lean on us, work alongside us increasingly, and hand us more patients as we grow in scale. At a high level, those are the kinds of metrics we monitor. There's far more depth to what we examine. But on these calls, I'm eager to report our progress regarding how many patients have stayed with us, growth in the volume of patients being assigned to us, plus how many we're engaging, how many we're signing up for our remote patient monitoring and virtual care platform, how many we're providing cardiac monitoring to, and how many care gaps we're shutting. And in the end, the contracts we hold can develop into us turning into the primary care provider of record, potentially with us sharing in cost savings along with value-based rate arrangements and value-based care. So there's substantial runway for us in this segment; we're quite enthusiastic about it, and we're also delivering enormous benefit to the patients we visit, since we're closing meaningful care gaps and probably catching catastrophic — potentially catastrophic episodes before they reach that point — for instance, our diabetic retinal exams are catching blindness, potential blindness or potential vision impairment before it occurs. And that clearly grows expensive and is a terrible outcome for a patient; so we're extremely pleased with the momentum, with the metrics. We're pleased with the excellent care we deliver and the good we do for patients. And so we believe there's plenty of runway, plenty of growth, and plenty of good to accomplish in the quarters ahead, and I'm eager to share that progress as we expand. Roughly 68,000 lives assigned.

David Grossman

analyst
#23

So maybe we're jumping the gun here, but can you give us any way to size up what's happening — maybe the pipeline measured by lives, or some other hard numbers — so we get a clearer picture of how this business is scaling?

Lee Bienstock

executive
#24

Once patients get assigned to us, we'll report the figure — both the count of lives and the count of assigned patients. Between all of our partners, there are millions of lives available to be assigned for closing care gaps. And from where I sit, we've barely begun to tap that potential. To accomplish what's possible, the effort has to scale. Our patient engagement team has to scale. Our field team must keep scaling as well. We're already putting substantial money into our technology platform and our clinicians, and that spending can keep going; and I can tell you that each of the partners we work with has many hundreds of thousands of patients, and when you look at our bigger partners, they have more than 1 million patients apiece. So in terms of the good we could deliver there, we've only just started. And pinning down the exact metrics for that funnel I just walked through is premature, I think, but we will absolutely provide that in the quarters ahead.

Ryan MacDonald

analyst
#25

Ryan, thanks for the kind words about the quarter. I appreciate you laying out the strategic vision and highlighting the 3 main areas we're concentrating on: insurance partners, municipalities, and health systems. When you think about how we allocate our time and where the greatest opportunity lies, how would you order those 3 in terms of future pipeline or backlog potential?

Lee Bienstock

executive
#26

Thanks for asking, Ryan. I'm not going to rank the customer segments, because we care about them equally, so to speak, and we value every one of our partners. When I look at it, clearly, as we've shared, most of our revenue today comes from health systems and municipalities. But we're seeing enormous — our growth rates are extremely high with the third pillar, the value-based care insurer group. So I don't think I'd put one above another, because our aim is to deliver an absolutely outstanding customer experience; that's ingrained in our culture for every customer, regardless of size — whether they're big or small, we've provided an absolutely outstanding customer experience, which is why they tend to expand with us. And a small customer today might become a very big customer down the road. That's how we see it. I will say we keep submitting proposals across all 3; we have growth strategies for all 3. We're putting investment into growth in all 3. And so I think what you're seeing — to get more directly at your question — is that the big contract wins, the dollar-value contract wins, are coming from health systems, our hospital partners, and municipalities. The contracts we're winning, negotiating, and have in the pipeline with the insurers could become very large as we scale them and as we're able to take on more and more patients — then they'll bring more associated revenue figures and growth for them. So we're going to invest in that. But the wins right now — and the dollar wins — are coming from the first 2. I'd also say the expansion opportunities and the market potential are coming from that third pillar with the insurance providers too.

Ryan MacDonald

analyst
#27

Then, for a follow-up, earlier this year at the Investor Day, you had sort of laid out the path toward adjusted EBITDA margins of 20%, as you exit 2025, and that really rested on a gross margin profile of 40%. With the top-line success you keep having, plus some of the temporary margin pressure that comes with it, do you still see that 40% gross margin, 20% EBITDA margin target as structurally achievable for the business today?

Lee Bienstock

executive
#28

They are structurally achievable — go ahead. Let me just say, Norm, that they are structurally achievable, and they remain our goals, as we stated at the Investor Day. But Norm, go ahead.

Norman Rosenberg

executive
#29

Yeah, that's basically right — I was about to make that point. The way we tend to think about it is this: on a consolidated, blended basis, gross margins run at approximately 40%, and SG&A would account for around another 20 points. On the SG&A side, we're more or less where we need to be, though we recognize we may need to move backward a bit before moving forward again — but we're quite close. Clearly, the bigger opportunity for improvement lies in gross margin. That said, we do believe it's achievable from a structural standpoint. And I'll simply repeat what Lee noted: this is absolutely our objective. It will certainly come down to absorbing some of the revenue gains we've seen recently and then pushing that figure upward; we have a good sense of where and how to accomplish it. The only question is when that top-line growth curve plays out, which will affect, in the short term, how near we come to hitting that target.

Pito Chickering

analyst
#30

Over the past several years, this model has changed shape a number of times — it began with COVID, then shifted toward homeless populations, and after that toward migrants. How should we view both homeless individuals and migrants as a driver of growth over the next few years? Also, could you discuss whom we're now seeing as competitors in those markets — say, for the border opportunity? At what point did the company secure that contract?

Lee Bienstock

executive
#31

Yes. Peter, I'll take that. Regarding the Border Patrol contract, it's still quite early; in the weeks and months ahead, we'll learn who came out on top; but I really want to note — let me begin by saying that with respect to the evolution you just described, we — our entire business, every segment, our full customer base, our markets, we're expanding at the target rate we published, even without the HPD asylum seeker contract. So clearly that has sped up our growth, but absent that HPD content, we would still be expanding at our target rate; so I want to be sure I convey that. And so when it comes to asylum seeker care, a great deal of transferable expertise has been brought by us to that contract; so to begin, there's a transportation element involved. And clearly, one of the biggest medical transportation providers in the nation. We make use of that, as I noted, that first paramedic BLS unit at the Port Authority where our transport teams — And we keep using our platform to assist the city in scaling care for this particular population. We rely on the same logistics platform. We rely on the same tech platform. We rely on the same vaccine management platform. And every single day we're expanding our capabilities that we're helping to provide the care for the asylum seekers but we're also using that same exact — those same exact competencies for other contracts. For instance, you can imagine casework and behavioral health care that we're providing at scale for asylum seekers also applies to patients of insurance providers and some of our other key customers; so we keep leveraging the capabilities we have across all of our segments. There's a common thread for all of the customers we partner with for all of the patients we're providing care. We leverage all the same platforms, all the same technology. And so that has enabled us to scale very, very rapidly in those investments in our people and our technology that have allowed us to do that; and we apply that to a myriad of different patient populations. And so I just want to be sure that I shared that, and I think that's a very key aspect of our growth and how we've been able to provide care for such a wide swath of patient needs.

Pito Chickering

analyst
#32

Then, another question regarding cash collections. I get the guidance toward recovery in Q4. But assuming you do bounce back or gather that money during Q4, would it be reasonable to assume that you — that the revolver you pulled on will get repaid? And regarding those hold-ups, what portion stems from the real-time audit being subtracted? You've stated very plainly that no disputes existed here, yet while undergoing a real-time audit, are you encountering any resistance from the state throughout that process? Just considering hotel prices pretty much in food or getting health care through telehealth or face-to-face?

Norman Rosenberg

executive
#33

Regarding your — the first quarter, to address your point, I don't want to corner this. I mean, it would make plenty of sense for us, as we produce additional working capital and more free cash flow, to apply that toward paying down the credit line. I mean, the credit line isn't viewed as something we intend to keep permanently; it's something available to provide us with some flexibility; so yes, obviously, we would repay it whenever we could. Regarding the other matter about how the real-time audit affects things, here's why I believe that effect occurs: I think it relates to the kind of backup requested on those invoices, and it's being done in preparation for the real-time audit. There's been no other indirect impact audit; and that's sort of an effect that typically fades over time, because once we establish a good rhythm with them concerning the kinds of backup we'll supply alongside our invoices, then we simply repeat it over and over as we move through the following month's invoice and the one after that. So it truly hasn't had a major effect on anything like that; it doesn't mean that may linger on each invoice longer. It really just means they'll make some additional requests for backup kind of upfront compared to what we would have otherwise anticipated providing. But that alone isn't truly a problem for us.

Richard Close

analyst
#34

Regarding the growth in backlog — and Lee, I appreciate what you said about the 3 channels — but is the bulk of that rise in the backlog figure you gave, I believe the $105 million increase, is it roughly an even division between municipalities in the government channel and the health systems? Or what's the right way to think about how that splits?

Norman Rosenberg

executive
#35

Richard, I'll handle that one. I have the backlog file open right here in front of me. So the back of — again, just to sort of refresh <<inaudible>> memory about how the mechanism works. Okay, so if nothing else changes, you'd expect the backlog number to go down, because more of it is turning into real revenue — and a good chunk of it did turn into real revenue this quarter. But even with that, we still added quite a bit to backlog from all the contracts we've picked up pretty much everywhere we operate and across all our business lines. So I'd say, especially in this quarter, the mix is a really big one. So a portion of the government work is clearly in play now for growth or more sites; that's obviously a big part of it. At the same time, though, there are a few contracts we landed in the U.K. As I believe we said earlier, those are extremely sizable agreements, the type that will benefit us. We've got a few involving Native American communities, plus additional sorts of efforts handled via another one of our entities. So what I'm saying is, this is material relevant to the U.S. and also relevant to the U.K. market. It's relevant to Mobile Health, and it's relevant to Transport. Honestly, it's distributed quite well across the board. Yet undeniably, a significant portion stems from our expectation of generating additional revenue from certain asylum projects, since the inflow has matched what we anticipated seeing. Even so, that factor isn't a major one by any standard. Given how varied the backlog is, it doesn't dominate as a source of it.

Lee Bienstock

executive
#36

Thanks. I appreciate everyone being here today. Many thanks to all of you. That means a lot. Talk to you shortly.

Operator

operator
#37

Appreciate it. That brings us to the end of today's call, everyone. Thanks for being with us. At this point, feel free to hang up your lines.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete DocGo Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

For developers and AI pipelines

Programmatic access to DocGo Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DocGo Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.